{"entity":{"id":"nct05948943","kind":"trial","name":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.","aka":[],"tldr":"A phase 2/3 trial of Alpelisib in childhood cancers, run by Novartis Pharmaceuticals, now recruiting.","summary":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. is a phase 2/3 interventional study registered as NCT05948943 by Novartis Pharmaceuticals, with 232 participants planned, started 2023-11-24 and due to reach its primary completion in 2028-05-31. Interventions recorded: Alpelisib and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05948943","url":"https://clinicaltrials.gov/study/NCT05948943"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":["alpelisib"],"companies":["advanced-accelerator-applications"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05948943","phase":"2/3","setting":"A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.","sponsor":"Novartis Pharmaceuticals","enrolled":232,"outcomes":[]},"route":"/trials/nct05948943/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"}],"drug":[{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"}]}}